Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline. Bayer will pay $425 million up front and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results